-
Mashup Score: 3Bulevirtide Demonstrates Sustained Efficacy, Safety for Chronic Hepatitis D Patients - 10 month(s) ago
The investigational therapy from Gilead showed effectiveness and safety at 96 weeks.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0COVID Hosp Expert Roundtable — Current Activities - 10 month(s) ago
Seeing the Forest Through the Trees: Therapeutic Approaches for Hospitalized Patients with COVID-19 This activity is jointly provided by National Jewish Health (NJH) and Bonum CE. …
Source: Current ActivitiesCategories: Critical Care, Latest HeadlinesTweet-
Coming soon... 🏥#MedTwitter Expert Roundtable - Hosp'd Pts w COVID-19 w/⭐️me, @WrayCharles +@DrOnyemaOgbuagu Supported by an edu grant from #Gilead Sci, Inc 📝Next... 1:🟢Answer PRE-polls👇 OR 🆓 #CME👉https://t.co/6NDVz7qZMc 2:🗓️Watch video 3:🔴Answer post-polls 4:🏆Claim CME
-
-
Mashup Score: 0COVID Hosp Expert Roundtable — Current Activities - 10 month(s) ago
Seeing the Forest Through the Trees: Therapeutic Approaches for Hospitalized Patients with COVID-19 This activity is jointly provided by National Jewish Health (NJH) and Bonum CE. …
Source: Current ActivitiesCategories: Infectious Disease, Latest HeadlinesTweet-
Coming soon... 🏥#MedTwitter Expert Roundtable - Hosp'd Pts w COVID-19 w/⭐️Me @NidaQadirMD + @WrayCharles Supported by an edu grant from #Gilead Sci, Inc 📝Next... 1:🟢Answer PRE-polls👇 OR 🆓 #CME👉https://t.co/3A5d2wjIDq 2:🗓️Watch video 3:🔴Answer post-polls 4:🏆Claim CME
-
-
Mashup Score: 0
-
“🏥#CrackTheCase Hospitalized Pts w/ COVID-19 – Day 1️⃣ – Best practices for mgmt of immunocompromised, critically-ill patients w/⭐️@NidaQadirMD; @WrayCharles; @DrOnyemaOgbuagu; @BonumCe https://t.co/DIPWorVMuh”
Read the original tweet here
Source: TwitterCategories: Infectious Disease, Latest HeadlinesTweet-
2/#MedTwitter #IDTwitter #IDMedEd #FOAMCC 1️⃣Answer pre-polls👇 2️⃣Watch day 1🎥https://t.co/oT1LlXwRRo 3️⃣Watch day 2📽️👆 4️⃣Claim CME 🏆https://t.co/yUGTMnfNGc Supported by an educational grant from #Gilead Sciences, Inc. 📸Faculty disclosures & CMEℹ️ https://t.co/2JSq0TtsmH
-
-
Mashup Score: 222012a - Crack the Case #2 — Current Activities - 12 month(s) ago
Seeing the Forest Through the Trees: Therapeutic Approaches for Hospitalized Patients with COVID-19 This activity is jointly provided by National Jewish Health (NJH) and Bonum CE. …
Source: Current ActivitiesCategories: Infectious Disease, Latest HeadlinesTweet-
4/#MedTwitter #IDTwitter @toddlee @AneeshMehtaMD @KariTikkinen #CME🏅➡️https://t.co/yUGTMnfNGc 🟢Pre-Poll 2️⃣ For critically ill pts w COVID-19 & ARDS, which treatment/s are recommended in addition to corticosteroids? abx=antibiotic, BAR=baricitinib, TOCI= tocilizumab
-
3/#CME🏅➡️https://t.co/yUGTMnfNGc 📟Paging experts to weigh in & 💬@AngelaBrancheMD @PaulSaxMD @HelenChuMD 🟢Pre-Poll 1️⃣ What is the most appropriate treatment for hospitalized pts w COVID who require low-flow O2? DEX=Decadron/dexamethasone
-
2/#MedTwitter #IDTwitter 1️⃣Answer pre-polls👇 2️⃣Watch📽️👆 3️⃣Come back tmrw👂best practices 4️⃣Claim #CME 🏆https://t.co/yUGTMnfNGc Supported by an independent edu grant from #Gilead Sciences, Inc. 📸Faculty disclosures & #CME ℹ️ https://t.co/Pb22s601mQ
-
#MedTwitter #IDTwitter #PulmTwitter 🤨How to manage a crit ill pt w COVID? 🗓️Join @NidaQadirMD tmrw, Day 2️⃣→learn best practices 🆓#CME👉 https://t.co/yUGTMnfNGc 🟢What's your specialty?
-
4/#MedTwitter #IDTwitter @toddlee @AneeshMehtaMD @KariTikkinen #CME🏅➡️https://t.co/QgXU3gLJGb 🟢Pre-Poll 2️⃣ For critically ill pts w COVID-19 & ARDS, which treatment/s are recommended in addition to corticosteroids? abx=antibiotic, BAR=baricitinib, TOCI= tocilizumab
-
3/#CME🏅➡️https://t.co/QgXU3gLJGb 📟Paging experts to weigh in & 💬 @CamWolfe @AngelaBrancheMD @doctorfungus @HelenChuMD @DrAndreKalil 🟢Pre-Poll 1️⃣ What is the most appropriate treatment for hospitalized pts w COVID who require low-flow O2? DEX=Decadron/dexamethasone
-
2/#MedTwitter #IDTwitter 1️⃣Answer pre-polls👇 2️⃣Watch📽️👆 3️⃣Come back tmrw👂best practices 4️⃣Claim #CME 🏆https://t.co/QgXU3gLJGb Supported by an independent edu grant from #Gilead Sciences, Inc. 📸Faculty disclosures & #CME ℹ️ https://t.co/9pAdJbY7RC
-
#MedTwitter #IDTwitter #PulmTwitter 🤨How to manage a crit ill pt w COVID? 🗓️Join tmrw, Day 2→learn best practices 🆓#CME👉 https://t.co/vXf4yYBJRB 📟Paging experts to ⚖️ in 📟@nickmmark @WesElyMD @PulmCrit @Paul_Wischmeyer @PilarRiveraOrt1 @EM_RESUS 🟢What's your specialty?
-
-
Mashup Score: 0
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Infectious Disease, Latest HeadlinesTweet-
1/#MedTwitter #IDTwitter #IDMedEd #InternalMedicine #Hospitalists It's as easy as 1️⃣2️⃣3️⃣ 1️⃣Watch📽️👆 2️⃣Answer the post-polls🗳️👇 3️⃣Claim #CME @ https://t.co/Wr8JTklHa4 📸Faculty disclosures & #CME ℹ️👇 Supported by an independent edu grant from #Gilead https://t.co/k4Na1VUXz8
-
-
Mashup Score: 0Crack the Case #1 — Current Activities - 1 year(s) ago
This CME-certified, video reviews a patient case and the best practices for treatment and staging based on the latest clinical guidance regarding severity assessments for hospitalized patients with COVID-19.
Source: Current ActivitiesCategories: Infectious Disease, Latest HeadlinesTweet-
5/#MedTwitter #IDTwitter #IDMedEd #IDFellow #IMResident #InternalMedicine #Hospitalists #BonumCE #FOAMCC #CME🏅➡️https://t.co/DGYeVFJ53J 🟢Pre-poll Q 2️⃣ ❓For a COVID+ patient, which of the following are considered risks for disease progression?
-
4/#MedTwitter #IDTwitter #IDMedEd #IDFellow #IMResident #InternalMedicine #Hospitalists @BonumCe #CME➡️https://t.co/DGYeVFJ53J 🟢Pre-Poll1️⃣ ❓@NIH guidelines recommend which tx for pts w/ mild/moderate #COVID19 infection, no O2 supp, but who have high risk for progression?
-
3/#MedTwitter #IDTwitter #IDMedEd #IDFellow #IMResident #InternalMedicine #Hospitalists @BonumCe #CME➡️https://t.co/DGYeVFJ53J 🗳️pre-polls👇 🟢What’s your specialty?
-
2/#MedTwitter #IDTwitter #IDMedEd #InternalMedicine #Hospitalists 1️⃣Answer pre-polls👇 2️⃣Watch📽️👆 3️⃣Come back tmrw👂RE: best practices in stging & mgmt 4️⃣Claim #CME https://t.co/DGYeVFJ53J 📸Faculty disclosures & #CME ℹ️ Supported by an independent edu grant from #Gilead https://t.co/thzvTgUrcq
-
-
Mashup Score: 4Gilead Submits FDA NDA for Lenacapavir - 3 year(s) ago
The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Gilead submits for #FDA NDA for #lenacapavir https://t.co/BMog7eiwUc
-
-
Mashup Score: 1
Looking at data from 3 analyses showed a reduction in mortality was observed across a spectrum of baseline oxygen requirements, at different timeframes, over the course of the pandemic, and in various geographies.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Gilead announced today positive data from 3 retrospective studies, which observed that hospitalized patients who received #remdesivir had significantly lower risk for mortality compared with matched controls. #COVID19 https://t.co/Rx5hwE0lG8
-
-
Mashup Score: 2
Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release. The announcement puts an official end to a years-long competition between Gilead and AbbVie, whose upadacitinib (Rinvoq) won the race to enter the drug market as the third JAK inhibitor approved by
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Gilead announced it will no longer pursue #FDA approval for its JAK inhibitor #filgotinib in the treatment of #rheumatoidarthritis. Trials for psoriatic #arthritis, ankylosing spondylitis and non-infectious uveitis ending. IBD approval efforts continue. https://t.co/DYokOBs2Mo
-
For people with chronic #hepatitis D, #bulevirtide from #Gilead was found to be safe and efficacious at Week 96 according to data presented at the recent European Association for the Study of the Liver Congress 2023. https://t.co/a8fbEqVCQu https://t.co/TFd3TkJ0Rv